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A B S T R A C TObjectives: In many countries, such as Ghana, there is an increasing
impetus to use economic evaluation to allow more explicit and trans-
parent health care priority setting. An important question for policymakers
in low-income countries, however, is whether it is possible to introduce
economic evaluation data into health care priority-setting decisions.
Methods: This article systematically reviewed the literature on economic
evaluation on medical devices and pharmaceuticals in Ghana published
between 1997 and 2012. Its aim was to analyze the quantity, quality, and
targeting of economic evaluation studies that relate tomedical devices and
pharmaceuticals and provide a framework for those conducting similar
health technology assessment reviews in similar contexts. Results: The
review revealed that the number of publications reporting economic eval-
uations was minimal with regard to medical devices and pharmaceuticals.
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ondence to: Emmanuel Ankrah Odame, Ghana CollScheme since 2004 policymakers are confronted with the challenge of
allocating scarce resources rationally. Priority setting therefore has to be
guided by a sound knowledge of the costs of providing health services. The
need for economic evaluation is thus important. More costing studies were
found; there were very few cost-effectiveness analysis studies. If economic
evaluation is useful for policymakers only when performed correctly and
reported accurately, these ﬁndings depict barriers to using economic
evaluation to assist decision-making processes in Ghana; hence, there is
a need for an independent health technology assessment unit.
Keywords: economic evaluation, Ghana, medical devices, pharma-
ceuticals.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Modern health care is cost and technology intensive and expects
value for money, creating demand for evidence-based practice
and health technology assessment (HTA). In high-income coun-
tries, HTA is often done in specialized HTA institutions. In
developing countries, however, HTA is often lacking, despite
the apparent need. Therefore, health care decisions are often
subjective. Improved understanding of the practice of evidence-
based medicine (EBM) in many developing countries, and organ-
izations such as the Cochrane Collaboration, now facilitate
evidence-informed decisions [5].
HTA is the scientiﬁc process of evaluating health technologies
(pharmaceuticals, vaccines, surgical procedures, medical equip-
ment and devices, etc.) to facilitate informed decisions by stake-
holders: health care providers, payers, consumers, regulators,
policymakers, and so on [1]. In high-income countries, HTA is a
formal discipline undertaken by trained professionals to guide
stakeholders, including governments, to make decisions on the
basis of sound scientiﬁc principles. Most resource-poor settings lack
formal HTAmechanisms; in such settings, health care decisions are
often based on no evidence and are more subjective. A recent
survey [9] evaluating the use of key HTA principles [2] reported that
even in the few developing countries in which HTA is being used,although the principles were considered relevant by HTA producers
and users, the level of application was uniformly low.
Although resource allocation for health and demand for new
health technologies have increased in many low-income coun-
tries, robust decision-making mechanisms have not developed in
parallel. Decisions are often driven by experience, thrust of donor
agencies, and lobbying pressure [6]. For example, a report from
Peru noted that decisions on the human papilloma virus vaccine
at the local level were mainly driven by local political pressure
rather than scientiﬁc evidence [11]. In Rwanda, the government
had allocated a disproportionately large amount of funds for HIV/
AIDS than for malaria and other greater perceived needs, because
donor grants were speciﬁcally allocated for HIV/AIDS [22]. Like-
wise in India, sustained single-point focus on poliomyelitis
eradication using supplementary immunization (owing to World
Health Organization and global pressure) has critically weakened
the routine immunization program with other childhood vac-
cines [20].
Commercial pressure is also a major force skewing the
decision-making process in developing countries; this is especially
relevant for newer vaccines, expensive drugs, devices, and equip-
ment [24]. For example, current immunization recommendations
of the Indian Academy of Pediatrics were produced by expert
consensus at a meeting sponsored by a multinational company.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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to produce guidance for three products recently marketed by the
company in India [15].
Although poorer countries should be more careful in spending
money, the opposite often happens in most instances. Health care
systems sometimes successfully negotiate lower pricing for phar-
maceuticals, but public health programs end up paying more than
the negotiated prices [16]. Such observations corroborate the
argument of Chalkidou et al. [6] that in many developing countries,
“health services and technologies purchased with public funds are
selected through idiosyncratic processes that often have little to
do with systematic analysis of their potential health beneﬁt or
value for money.” In many developing countries, “expert-based”
guidance is used as a surrogate for robust methods, perhaps in
good faith [12]. A group of “experts” prepares a “consensus” state-
ment on a given health technology. The procedure for selecting
the experts and the processes used to reach consensus are seldom
described [15]. In developing countries, physicians often base their
“advice” on nonscientiﬁc considerations, particularly the inﬂuence
of the pharmaceutical industry [21]. Material provided by pharma-
ceutical manufacturers is reported as the most frequently used
resource by many physicians, with prescribing decisions inﬂu-
enced by training activities sponsored by pharmaceutical compa-
nies and visits by sales representatives [21].
In Ghana, a National Health Insurance Scheme (NHIS) was
established in 2004, and the Ghana Diagnostic Related Group
provider payment mechanism has been fully implemented, and
although there are a number of challenges, the payment system
is functioning well and generally accepted by providers. It has
not, however, succeeded in containing costs, particularly for
outpatient services, with outpatient claims now accounting for
70% of total NHIS claims and 30% of total costs of the NHIS.
Furthermore, between 2007 and 2009, the average outpatient cost
per claim increased by nearly 50% from US$3.47 to US$5.06.
Without a control of the rapid rise in service delivery costs of
the NHIS, in addition to mobilization of more revenue, the
scheme will not be sustainable [29].
Meanwhile, to date there is no institution that does cost
-effectiveness analysis of the pharmaceuticals that are part of
the beneﬁt package. There is no evidence base guiding the drugs
that are part of the beneﬁt package.
Clearly, health care decisions by all stakeholders in Ghana are
often highly subjective. There is an urgent need to bring in
objectivity, reproducibility, and transparency. HTA as a scientiﬁc
process of evaluating health technologies (pharmaceuticals, vac-
cines, surgical procedures, medical equipment and devices, etc.)
to facilitate informed decisions by stakeholders—health care
providers, payers, consumers, regulators, policymakers, and so
on—can address this need. Hence, the need of this systematic
review to critically evaluate the evidence base of cost-
effectiveness analysis of medical devices, vaccines, pharmaceut-
icals, and surgical procedures.Methods
Literature searches were carried out in November 2012 by using
the following keywords: “Ghana” and “economic evaluation” or
“cost-minimisation” or “cost-effectiveness” or “cost-utility” or
“cost-beneﬁt.” The search was performed by using the following
databases: PubMed, EMBASE (Ovid), and Academic Search Elite
(EbscoH). It included all published and unpublished literature
available between January 1, 1997, and October 31, 2012. Inclusion
criteria were all economic evaluations on medical devices and
pharmaceuticals including vaccines.
All identiﬁed abstracts were reviewed by the ﬁrst author.
Studies were excluded if they did not present both the costsand the outcomes of a study, or if they were an editorial or
methodological article. Studies were also rejected if they were not
applied to a Ghanaian context and all other economic evaluations
apart from medical devices, vaccines, and pharmaceuticals. All
remaining articles were reviewed by using their full-text formats
and classiﬁed according to: 1) the type of evaluation, 2) the type of
intervention, and (3) the body system affected by the particular
health problem.
Published articles were grouped by type of evaluation, and
were considered to be: 1) a partial economic evaluation if only
either the costs or the outcomes of a single intervention were
compared; 2) a cost-minimization analysis if costs of different
interventions were compared with evidence of equal ease burden
in terms of disability-adjusted life-years; 3) a cost-effectiveness
analysis if health outcomes were presented in intermediate
terms, for example, disease prevented; (4) a cost-utility analysis
if health outcomes were expressed in terms of quality-adjusted
life-years or disability-adjusted life-years; and 5) a cost-beneﬁt
analysis if health outcomes were measured in monetary units.
Only those studies that did economic evaluation in relation to
medical devices, pharmaceuticals, and vaccines were considered.
The quality of studies was measured in two different ways.
First, studies were appraised on their adherence to speciﬁc
methodological and reporting practices based on published rec-
ommendations [7,8]. These included: 1) clearly indicating the
study perspective; 2) description of comparator(s); 3) use of
discounting methods if the costs and/or outcomes were from a
study period of more than 1 year; 4) reporting the incremental
cost-effectiveness ratio (ICER) rather than the average cost-
effectiveness ratio; 5) performing uncertainty analysis on the
results; and 6) disclosing funding sources.Results
A total of 50 abstracts were identiﬁed from the search of both
published and unpublished material (Fig. 1).
Of these, 45 abstracts were initially excluded because costs
and outcomes were not mentioned simultaneously and because
they disclosed funding sources. Seven articles were reviewed in
full-text format. From the review of seven full-text articles, four
articles were found not to be relevant because they were not
economic evaluations of medical devices and pharmaceuticals
including vaccines. The culmination of this was three economic
evaluations, one looked at vaccines and two on malaria
management.
In terms of where they were published, international peer
review was the source and an international person was the
principal author for two of them, with a Ghanaian author as the
principal author for one of them. All three economic evaluations
were cost- effectiveness analysis. Two of them used an ICER.
International standards recommend that economic evalua-
tion studies should extend (through modeling) over a time period
that is long enough to capture the full costs and consequences of
an intervention. The funding sources were all from international
nonproﬁt organizations.
There was no signiﬁcant relationship between the source of
funding and the quality of the report (using chi-square and
Fisher’s exact tests, where appropriate). See Table 1.Discussion
HTA is the scientiﬁc process of evaluating health technologies
(pharmaceuticals, vaccines, surgical procedures, medical equip-
ment and devices, etc.) to facilitate informed decisions by stake-
holders: health care providers, payers, consumers, regulators,
50 abstracts were identified
45 abstracts were excluded
2 articles were identified from references of the initially
searched articles
5 full articles were reviewed
3 economic evaluation publications were
finally reviewed
4 articles excluded after reviewing their full
texts
Fig. 1 – Flow diagram of systematic review.
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for medical purposes in patients, diagnosis, therapy, or surgery.
Pharmaceutical products achieve their principal action by phar-
macological, metabolic, or immunological means. However, med-
ical devices act by other means such as physical, mechanical,
thermal, physicochemical, or chemical [28]. A survey of experts,
conducted by Daar et al. [29], clearly showed the greatest need of
new technology for affordable, simple diagnosis of infectious
diseases in developing countries.
From the systematic review it is evidently clear that very
scanty technology assessment has been done for medical devices
and pharmaceuticals. In Ghana, currently with the NHIS the cost
of medicines is a major cost driver, but evaluation of medicines as
part of the beneﬁt package is done without a robust evidence
base. In this age in which there are multiple solutions and
generally a wide spectrum of possibilities and strategies for most
health care problems, the need for the evaluation of the technol-
ogy and of the relevant alternative technologies available has
never been greater. Second, as the health sector has limited
budgets, HTA becomes one of the most important tools used to
contain the increasing cost of health care without compromising
safety. HTA should form the basis for health technology policies
[2]. Prioritizing resource allocation and the need for new medical
technologies are also increasing in developing countries [3].
Health insurance programs are emerging and expanding in sub-
Saharan Africa [6]. Besides, health insurance programs are emerg-
ing and expanding more and more in this region [27]. But decis-
ions can easily be inﬂuenced by experience, thrust of donor
agencies, and lobbying pressure for new technologies, for exam-
ple, from commercial organizations. This can lead to inappropri-
ate use of technologies, which do not address health needs, and
inefﬁcient use of resources. Pichon-Riviere et al.’s [9] survey about
the usage of HTA methods in a resource-poor setting suggested
that principles of HTA were seen as relevant, but there was a lack
of application. South Africa, as a middle-income coun-
try, however, has planned strategies for HTA. Yet, the implemen-
tation of such a national HTA framework has been slow. The lack
of skills related to HTA is also a critical problem. Although there is
a growing base of skills in the running of clinical trials, there are
very few health economists trained in applying HTA method-
ologies. In Ghana, there was some training on pharmacoeconom-
ics organized by the Ministry of Health, but the follow-up
activities have not been sustained.
The emergence and spread of EBM was expected to address
relevant needs, through building local capacity for using system-
atic reviews and inﬂuencing policymakers to make evidence-
based decisions. However, EBM has major limitations in that it
focuses on generating evidence of efﬁcacy alone. In addition, itfails to factor in local needs and contexts for transferability of
evidence generated in different health care settings [5]. The
development process of HTA is usually expensive and time
consuming [6], which poses problems in many resource-poor
settings. In Ghana, as in other low- and middle-income African
countries, policymakers have in recent years come under increas-
ing pressure to justify resource allocation decisions in the health
sector [26]. The number of economic evaluation studies in Ghana
is quite low, however, especially in the area of medical devices,
vaccines, and pharmaceuticals, in contrast to Canada, the United
Kingdom, or The Netherlands [17] where economic evaluation has
been formally accepted for use in policy decision making. In
addition, this review found that the majority of economic evalua-
tion studies performed in Ghana between January 1, 1997, and
October 31, 2012, were vulnerable to bias because of the quality of
the evidence used. Poor reporting quality limits the usefulness of
economic assessment in the making of policy decisions.
Evidence-based policy according to scientiﬁc methods can
reduce costs and improve the outcome for patients. Such analysis
thus provides an ethical way of evaluating new health technol-
ogies. Therefore, the participation of health care authorities in
Ghana is crucial. There is an urgent need to bring in objectivity,
reproducibility, and transparency for local health policy makers
in Ghana.
The review indicates that cost-effectiveness analysis was the
only study type for economic evaluations performed in a Gha-
naian setting for the study period. This is comparable to ﬁndings
in other settings [13,14], probably because the approach is
relatively straightforward. It compares costs with outcomes
measured in natural units, such as per life saved, per case
detected, and per pain- or symptom-free day.
This is in contrast to cost-utility analyses (which require more
assumptions on health-state preferences [18]) and cost-beneﬁt
approaches (which face difﬁculties and controversy in applying a
monetary value to human life [19]).
Cost-effectiveness analysis can be very useful when different
health care interventions are not expected to produce the same
outcomes. This type of study alone, however, cannot handle
questions of efﬁciency of resource allocation when such deci-
sions have to be made across different health problems [23].
In both technical and resource-allocation terms, there is a
need to encourage and support the undertaking of cost-utility or
cost-beneﬁt analyses by academics and health researchers
because these evaluation types are better able to assist decision
makers in judgments about the allocation of resources across
health care programs.
In addition, this review highlights that serious attention needs
to be given to the quality of the reporting and information used in
Table 1 – Type of economic evaluation and their characteristics.
Type of evaluation by year of
publication
Type of uncertainity analysis Use of
ICER
Discount
rate used
Funding source
Cost-effectiveness analysis published
in 2010
Probabilistic sensitivity analysis ICER used 3% International funding
agency
Cost-effectiveness analysis published
in 2012
One-way and multiway sensitivity
analysis
ICER used 3% International funding
agency
Cost-effectiveness analysis published
in 2012
One-way and multiway sensitivity
analysis
ICER not
used
3% International funding
agency
ICER, incremental cost-effectiveness ratio.
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tages of using systematic reviews of clinical effects are twofold
[4]. First, a more precise estimate can be obtained from combin-
ing outcome data from a number of studies. Second, by using
results from studies carried out in a range of settings (assuming
that these studies are sufﬁciently homogenous to be compara-
ble), the estimate can be applied to a more general patient
population with different baseline risks, rather than speciﬁcally
to the narrow population selected for individual economic eval-
uations as was observed in the studies trial.
It is noteworthy that there were two serious methodological
pitfalls that were commonly found in the Ghanaian economic
evaluations. The ﬁrst was the lack of calculation of an ICER in one
of the studies. This study reported an average cost-effectiveness
ratio, that is, total cost divided by total effect for the interventions
being compared. The report of an average ratio may lead to
dangerously ﬂawed conclusions and may limit attempts to make
direct comparisons between interventions because an average
ratio implies the comparison of each alternative with an inter-
vention that incurs no costs and no effects [10]. Without calcu-
lating and presenting ICERs, it is possible for readers to be
misguided by the results and to conclude that the new technique
was simply fourfold more expensive than the standard test.
Combined with the use of poor-quality evidence for estimat-
ing clinical effects, this could seriously undermine conﬁdence in
the ﬁndings of these economic evaluations and their ability to
inform health care resource-allocation decisions.
Among the studies that applied discounting, the review also
found that the discount rate used was 3%. There is still no
international agreement, however, on how to deal with future
costs and beneﬁts.
Major debate continues about whether it is justiﬁed to
discount health beneﬁts, and if so, what discount rate should
be used and whether it should be different from that used for
monetary costs [3]. Nevertheless, this review of the literature on
economic evaluations performed in Ghanaian settings has shown
limited evidence of economic evaluation publications with regard
to medical devices and pharmaceuticals.
It is important to point out the limitations of this study. There
is no national database for health care publications in Ghana.
This study searched the literature in international databases and
only included literature published in English and also unpub-
lished literature in some of the university campuses. The use of
these databases also meant that abstracts, conference proceed-
ings, Ghanaian publications, masters and doctorate theses, and
articles presented at symposia or seminars were not included in
the search results. The number of publications available, how-
ever, can be used as a proxy to reﬂect the research capacity in
this ﬁeld in Ghana, and this review has shown that the quantity,
quality, and targeting of economic evaluation studies is not yet
adequate to meet the needs and concerns of decision makers in
Ghana. Current studies support the establishment of HTA insti-
tutions in low- and middle-income countries [25].Conclusions
This review demonstrates an urgent need for a comprehensive
and systematic method for conducting economic evaluations for
medical devices and pharmaceuticals, especially in an era of
increasing cost in the Ghanaian health care system and also
dwindling donor support to the health sector. HTA of medical
devices and pharmaceuticals seems the most viable option to
ensure cost-containment, which is the main agenda of the NHIS,
and ultimately save the health care system.Acknowledgment
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